Expert committee recommendations for acne management

Pediatrics

Volumn 118, Issue 3, 2006, Pages 1188-1199

  Zaenglein, Andrea L ^a   Thiboutot, Diane M ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Acne vulgaris; Antimicrobials; Combination therapy; Maintenance therapy; Pathophysiology; Retinoids

Indexed keywords

ADAPALENE; AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BENZAMYCIN; BENZOYL PEROXIDE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GYRASE INHIBITOR; ISOTRETINOIN; LYMECYCLINE; MACROLIDE; MINOCYCLINE; ORAL CONTRACEPTIVE AGENT; OXYTETRACYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOIC ACID; RETINOID; RETINOID DERIVATIVE; SULFONAMIDE; SULFUR; TAZAROTENE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; UNINDEXED DRUG;

ACNE; BURN; CANDIDIASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMEDO; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DESQUAMATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULARY; DRUG MECHANISM; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ERYTHEMA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERPIGMENTATION; LUPUS LIKE SYNDROME; MEDICAL EXPERT; MEDICAL SOCIETY; MEDICAL SPECIALIST; META ANALYSIS; MONOTHERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN IRRITATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; ACNE VULGARIS; ADOLESCENT; ADULT; CHILD; DRUG COMBINATION; ORAL DRUG ADMINISTRATION;

ACNE VULGARIS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; DRUG THERAPY, COMBINATION; HUMANS; RETINOIDS;

EID: 33749077156     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-2022     Document Type: Review

References (82)

1. Leyden JJ. New understandings of the pathogenesis of acne. J Am Acad Dermatol. 1995;32:S15-S25
2. Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J. 1979;1(6171):1109-1110
3. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1 suppl):S1-S37
4. Pochi PE, Strauss JS, Downing DT. Age-related changes in sebaceous gland activity. J Invest Dermatol. 1979;73:108-111
5. Pochi PE, Strauss JS. Endocrinologic control of the development and activity of the human sebaceous gland. J Invest Dermatol. 1974;62:191-201
6. Gollnick HPM, Zouboulis CC, Akamatsu H, Kurokawa I, Schulte A. Pathogenesis and pathogenesis related treatment of acne. J Dermatol. 1991;18:489-499
7. Thiboutot D, Harris G, Iles V, Cimis G, Gilliland K, Hagari S. Activity of the type 1 5-α-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol. 1995;105:209-214
8. Thiboutot D, Knaggs H, Gilliland H, Lin G. Activity of 5-alpha-reductase and 17-beta-hydroxysteroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris. Dermatology. 1998;196:38-42
9. Thiboutot DM, Knaggs H, Gilliland K, Hagari S. Activity of type 1 5α-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol. 1997;136:166-171
10. Chen W, Zouboulis CC, Fritsch M, Kodelja V, Orfanos CE. Heterogeneity and quantitative differences of type 1 5α-reductase expression in cultured skin epithelial cells. Dermatology. 1998;196:51-52
11. Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol. 2001;116:793-800
12. Schmidt JB, Spona J, Huber J. Androgen receptor in hirsutism and acne. Gynecol Obstet Invest. 1986;22:206-211
13. Holmes RL, Williams M, Cunliffe WJ. Pilo-sebaceous duct obstruction and acne. Br J Dermatol. 1972;87:327-332
14. Plewig G, Fulton JE, Kligman AM. Cellular dynamics of comedo formation in acne vulgaris. Arch Dermatol Forsch. 1971;242:12-29
15. Kurokawa I, Mayer-da-Silva A, Gollnick H, Orfanos CE. Occurrence and distribution of cytokeratins and filaggrin in the human pilosebaceous unit: an immunocytochemical study. In: Marks R, Plewig G, eds. Acne and Related Disorders. London, England: Martin Dunitz; 1989:19-22
16. Cunliffe WJ, Holland DB, Clark SM, Stables GI. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol. 2000;142:1084-1091
17. Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol. 1975;65:382-384
18. Norris JF, Cunliffe WJ. A histological and immunocytochemical study of early acne lesions. Br J Dermatol. 1988;118:651-659
19. Toyoda M, Morohashi M. Pathogenesis of acne. Med Electron Microsc. 2001;34:29-40
20. Puhvel SM, Sakamoto M. The chemoattractant properties of comedonal components. J Invest Dermatol. 1978;71:324-329
21. Cunliffe WJ. The sebaceous gland and acne: 40 years on. Dermatology. 1998;196:9-15
22. Leyden JJ. Therapy for acne vulgaris. N Engl J Med. 1997;336:1156-1162
23. Draelos ZK. Patient compliance: enhancing clinician abilities and strategies. J Am Acad Dermatol. 1995;32:S42-S48
24. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology. 1998;196:119-125
25. Thielitz A, Helmdach M, Röpke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol. 2001;145:19-27
26. Verschoore M, Bouclier M, Czernielewski J, Hensby C. Topical retinoids: their uses in dermatology. Dermatol Clin. 1993;11:107-115
27. Hensby C, Cavey D, Bouclier M, et al. The in vivo and in vitro anti-inflammatory activity of CD271: a new retinoid-like modulator of cell differentiation. Agents Actions. 1990;29:56-58
28. Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol. 1969;99:469-476
29. Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol. 1996;34:482-485
30. Gollnick H, Schramm M. Topical therapy in acne. J Eur Acad Dermatol Venereol. 1998;11(suppl 1):S8-S12; discussion S28-S29
31. Mills OH Jr, Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol. 1978;58:555-557
32. Lucky AW, Cullen SI, Funicella T, Jarratt MT, Jones T, Reddick ME. Double-blind, vehicle-controlled multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol. 1998;38:S24-S30
33. Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter, double-blind, parallel study. J Am Acad Dermatol. 1998;38:S17-S23
34. Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol. 1998;139(suppl 52):8-11
35. Retin-A [package insert: full prescribing information]. Skillman, NJ: Ortho Dermatological; 2002
36. Dunlap FE, Mills OH, Tuley MR, Baker MD, Plott RT. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol. 1998;139(suppl 2):17-22
37. Weiss JS, Shavin JS. Adapalene for the treatment of acne vulgaris. J Am Acad Dermatol. 1998;39:S50-S54
38. Caron D, Sorba V, Kerrouche N, Clucas A. Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients. J Am Acad Dermatol. 1997;36:S110-S112
39. Millikan LE. Adapalene: an update on newer comparative studies between the various retinoids. Int J Dermatol. 2000;39:784-788
40. Clucas A, Verschoore M, Sorba V, Poncet M, Baker M, Czernielewski J. Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients J Am Acad Dermatol. 1997;36:S116-S118
41. Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol. 1997;36(suppl 2):S126-S134
42. Piérard-Franchimont C, Henry F, Fraiture AL, Fumal I, Piérard GE. Split-face clinical and bio-instrumental comparison of 0.1% adapalene and 0.05% tretinoin in facial acne. Dermatology. 1999;198:218-222
43. Galvin SA, Gilbert R, Baker M, Guibal F, Tuley MR. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol. 1998;139(suppl 52):34-40
44. Grosshans E, Marks R, Mascaro JM, et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol. 1998;139(suppl 52):26-33
45. Wolf JE. An update of recent clinical trials examining adapalene and acne. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):23-29
46. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 139(suppl 52):48-56, 1998
47. Thielitz A, Helmdach M, Rapke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Brit J Dermatol. 2001;145:19-27
48. Russell JJ. Topical therapy for acne. Am Fam Physician. 2000;61:357-365
49. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis. 1999;63:349-354
50. Bershad S. Topical retinoids in the treatment of acne vulgaris. Cutis. 1999;64(suppl 2):8-23
51. Kakita L. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris. J Am Acad Dermatol. 2000;43:S51-S54
52. Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A. 2005;136:117-121
53. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet. 1993;341:1181-1182
54. Selcen D, Seidman S, Nigro MA. Otocerebral anomalies associated with topical tretinoin use. Brain Dev. 2000;22:218-220
55. Zouboulis CC, Derumeaux L, Decroix J, Mariejewska-Udziela B, Cambazard F, Stuhlert A. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol. 2000;143:498-505
56. Wolf JE, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol. 2003;49(3 suppl):S211-S217
57. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed. 2005;4:138-146
58. Ozolins M, Eady EA, Avery AJ, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet. 2004;364:2188-2195
59. Meynadier J, Guillot B. Trétinoïne-érythromycine base: leur activité anti-inflammatoire. Gaz Med France. 1983;90:2551-2554
60. Parry MF, Rha C-K. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol. 1986;122:583-584
61. Kligman AM, Mills OH, McGinley KJ, Leyden JJ. Acne therapy with tretinoin in combination with antibiotics. Acta Derm Venereol Suppl (Stockh). 1975;74:111-115
62. White GM. Acne therapy. Adv Dermatol. 1999;14:29-58; discussion 59
63. Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol. 1995;132:204-208
64. Eady EA, Bojar RA, Jones CE, Cove JH, Holland KT, Cunliffe WJ. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol. 1996;134:107-113
65. Leyden JJ, Shalita AR. Rational therapy for acne vulgaris: an update on topical treatment. J Am Acad Dermatol. 1986;15:907-915
66. Kligman AM. Acne vulgaris: tricks and treatments. Part II: The benzoyl peroxide saga. Cutis. 1995;56:260-261
67. Gollnick HP, Graupe K, Zaumseil RP. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol. 2001;11:538-544
68. Espersen F. Resistance to antibiotics used in dermatological practice. Br J Dermatol. 1998;139:4-8
69. Eady EA, Jones CE, Tipper JL, Cove JH, Cunliffe WJ, Layton AM. Antibiotic resistant propionibacterium in acne: need for policies to modify antibiotic usage. BMJ. 1993;306:555-556
70. Eady EA. Bacterial resistance in acne. Dermatology. 1998;196:59-66
71. Meynadier J, Alirezai M. Systemic antibiotics for acne. Dermatology. 1998;196:135-139
72. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol. 1978;70:51-55
73. Esterly NB, Koransky JS, Furey NL, Trevisan M. Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol. 1984;120:1308-1313
74. Webster GF, McGinley KJ, Leyden JJ. Inhibition of lipase production in Propionibacterium acnes by sub-minimal-inhibitory concentrations of tetracycline and erythromycin. Br J Dermatol. 1981;104:453-457
75. Krowchuk DP. Treating acne: a practical guide. Med Clin North Am. 2000;84:811-828
76. Plewig G, Kligman AM. Acne and Rosacea. 3rd ed. New York, NY: Springer-Verlag; 2000
77. Goulden V, Glass D, Cunliffe WJ. Safety of long-term highdose minocycline in the treatment of acne. Br J Dermatol. 1996;134:693-695
78. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996;312:169-172
79. Grosshans E, Belaich S, Meynadier J, Alirezai M, Thomas L. A comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris. Eur J Dermatol. 1998;8:161-166
80. Landow K. Dispelling myths about acne. Postgrad Med. 1997;102:94-112
81. Thiboutot D, Pariser DM, Egan N, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol. 2006;54:242-250
82. Katsambas AD. Why and when the treatment of acne fails. Dermatology. 1998;196:158-161